Ribociclib
Ribociclib is a CDK4/6 inhibitor with demonstrated overall survival benefit across multiple Phase III trials (MONALEESA-2/3/7), making it one of the few targeted agents with confirmed OS improvement in HR+/HER2- breast cancer. Its pyrido[3,4-d]pyrimidine core provides tight CDK4/6 binding. QTc prolongation monitoring is required clinically.
Description
Scientific Overview: Ribociclib is a CDK4/6 inhibitor with demonstrated overall survival benefit across multiple Phase III trials (MONALEESA-2/3/7), making it one of the few targeted agents with confirmed OS improvement in HR+/HER2- breast cancer. Its pyrido[3,4-d]pyrimidine core provides tight CDK4/6 binding. QTc prolongation monitoring is required clinically.
Mechanism of Action: CDK4/6 Inhibitor
Purity: ≥99% | Molecular Formula: C23H30N8O
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | CDK4/6 Inhibitor |
|---|---|
| Purity | ≥99% |
| Molecular Formula | C23H30N8O |
| CAS Number | 1211441-98-3 |
